Communiqués de presse Archive - Page 15 of 19 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

OSE Immunotherapeutics Presents Positive Step-1 Phase 3 Results for Tedopi® in NSCLC

OSE Immunotherapeutics Reports First Half 2020 Results

OSE Immunotherapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

OSE Immunotherapeutics Publishes Positive Preclinical COVID-19 Vaccine Results

OSE Immunotherapeutics To Present Step-1 Results of Phase 3 Clinical Trial of Tedopi® ‘Atalante 1’

OSE Immunotherapeutics Receives €200,000 from Nantes Metropole to Develop CoVepiT

OSE Immunotherapeutics Announces Results of 2020 Virtual Combined General Meeting

OSE Immunotherapeutics Presents New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform

OSE Immunotherapeutics Identifies Monoclonal Antibody Antagonists of CLEC-1

OSE Immunotherapeutics Signs €7 Million Non-Dilutive Loan Agreement Guaranteed by the French State

Précédent
1
…
12
13
14
15
16
17
18
19
Suivant